沙库巴曲缬沙坦治疗Ⅱ型心肾综合征患者的临床疗效及对血管内皮生长因子的影响

doi:10.3969/j.issn.1006-6233.2026.02.027

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1196 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 探讨沙库巴曲缬沙坦治疗Ⅱ型心肾综合征患者的临床疗效及对血管内皮生长因子的影响。方法: 选择2024年4月至2025年2月收治的CRS-2患者144例,依据随机数字表法分为CG组、EG组,各组72例。CG均接受标准治疗,EG在标准治疗基础上加用沙库巴曲缬沙坦治疗。对比两组治疗前后心功能指标、动态心电图心率(AECG)、肾功能指标、血管内皮功能、肱动脉内血流介导的血管舒张功能(FMD)。结果: 与CG组比较EG组治疗前后SDNN、SDANN、rMSSD及PNN50差值明显增高(P<0.05);与CG组比较EG组治疗前后LVFS、LVEF及E/A差值明显增高(P<0.05);与CG组比较EG组治疗前后eGFR差值明显增高,与CG组比较EG组治疗前后BUN及Scr差值明显降低(P<0.05);与CG组比较EG组治疗前后EDD功能及D1差值明显增高(P<0.05),但两组患者D0差值比较无明显差异(P>0.05);与CG组比较EG组治疗前后CGRP及NO差值明显增高,与CG组比较EG组治疗前后ET差值明显降低(P<0.05)。结论: 沙库巴曲缬沙坦片通过多靶点调控机制,可同步优化CRS-2患者的心肾功能及血管内皮微环境,其疗效确切且安全性良好,为CRS-2的综合治疗提供了新的循证医学依据。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	马兰
	张志青

关键词 ： Ⅱ型心肾综合征, 沙库巴曲缬沙坦, 心功能, 肾功能, 血管内皮功能

Abstract：Objective: To investigate the clinical efficacy of sacubitril valsartan in patients with type II cardiorenal syndrome and its effect on vascular endothelial growth factor. Methods: A total of 144 patients with crs-2 admitted from April 2024 to February 2025 were selected and randomly divided into a control group and an experimental group, with 72 cases in each group. The control group received standard treatment, and the experimental group was treated with sacubitril valsartan on the basis of standard treatment. The indexes of cardiac function, Holter heart rate, renal function, vascular endothelial function, and brachial artery flow mediated vasodilation (FMD) were compared between the two groups before and after treatment. Results: Compared with the control group, the experimental group showed significantly higher differences in SDNN, SDANN, rMSSD, and PNN50 before and after treatment (P<0.05). The experimental group also exhibited significantly higher differences in LVFS, LVEF, and E/A ratio before and after treatment (P<0.05). The experimental group demonstrated significantly higher differences in eGFR before and after treatment, while showing significantly lower differences in BUN and Scr (P<0.05). The experimental group showed significantly higher differences in EDD function and D1 before and after treatment (P<0.05), but no significant differences in D0 values between the two groups (P>0.05). Compared with the control group, the experimental group showed significantly higher differences in CGRP and NO before and after treatment, while the experimental group showed significantly lower differences in ET (P<0.05). Conclusion: Sacubitril valsartan tablets can significantly improve cardiac function, renal function and vascular endothelial function in patients with crs-2, which is worthy of clinical application.

Key words： Type II cardiorenal syndrome Sacubitril valsartan Cardiac function Renal function Vascular endothelial function

基金资助:河北省医学科学研究课题计划资助,(编号20181090)

引用本文:

马兰, 张志青. 沙库巴曲缬沙坦治疗Ⅱ型心肾综合征患者的临床疗效及对血管内皮生长因子的影响[J]. 河北医学, 2026, 32(2): 341-347.
MA Lan, et al. Clinical Efficacy of Sacubitril/Valsartan in Patients with Type II Cardiorenal Syndrome and Its Effects on Vascular Endothelial Growth Factor. HeBei Med, 2026, 32(2): 341-347.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2026.02.027 或 http://www.hbyxzzs.cn/CN/Y2026/V32/I2/341

[1] 李嘉茵,赵钢.心肾综合征的中西医临床研究进展[J].中国医学创新,2023,20(1):169-173.
[2] 国家心血管病中心,中国心血管健康与疾病报告编写组.中国心血管健康与疾病报告2024概要[J].中国循环杂志,2025,40(6):521-559.
[3] Wang AY.Optimally managing hyperkalemia in patients with cardiorenal syndrome[J].Nephrol Dial Transplant,2019,34(3):36-44.
[4] McCallum W,Testani JM.Updates in cardiorenal syndrome[J].Med Clin North Am,2023,107(4):763-780.
[5] Hatamizadeh P.Cardiorenal syndrome:an important subject in nephrocardiology[J].Cardiol Clin,2021,39(3):455-469.
[6] Robles NR,Campillejo RD,Valladares J,et al.Sacubitril-valsartan improves anemia of cardiorenal syndrome(CRS)[J].Cardiovasc Hematol Agents Med Chem,2021,19(1):93-97.
[7] 中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.
[8] 王海燕.肾脏病学[J].中华医学杂志,1993,73(12):714-715.
[9] Celermajer DS,Sorensen KE,Gooch VM,et al.Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis[J].Lancet,1992,340(8828):1111-1115.
[10] Lim SY,Kim S.Pathophysiology of cardiorenal syndrome and use of diuretics and ultrafiltration as volume control[J].Korean Circ,2021,51(8):656-667.
[11] 张跃,李宁,邱健,等.血管紧张素受体脑啡肽酶抑制剂沙库巴曲缬沙坦治疗高血压的研究进展[J].中华高血压杂志,2021,29(6):6.
[12] Pfau D,Thorn SL,Zhang J,et al.Angiotensin receptor neprilysin inhibitor attenuates myocardial remodeling and improves infarct perfusion in experimental heart failure[J].Sci Rep,2019,9(1):5791.
[13] Kario K.The sacubitril/valsartan,a first-in-class,angiotensin receptor neprilysin inhibitor(ARNI):potential uses in hypertension,heart failure,and beyond[J].Curr Cardiol Rep,2018,20(1):5.
[14] Spatola L,Zeiler M,Granata A.Sacubitril/valsartan in dialysis patients:update on current perspectives[J].Cardiovasc Drugs Ther,2025,39(1):187-193.
[15] Usuda D,Higashikawa T,Hotchi Y,et al.Angiotensin receptor blocker neprilysin inhibitors[J].World Cardiol,2021,13(8):325-339.